CSL Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CSL Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'CSL Ltd - Product Pipeline Review - 2016', provides an overview of the CSL Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by CSL Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CSL Ltd
- The report provides overview of CSL Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses CSL Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features CSL Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate CSL Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for CSL Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CSL Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
CSL Ltd Snapshot 6
CSL Ltd Overview 6
Key Facts 6
CSL Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
CSL Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
CSL Ltd - Pipeline Products Glance 17
CSL Ltd - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
CSL Ltd - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
CSL Ltd - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
CSL Ltd - Drug Profiles 23
(coagulation factor II (human) + coagulation factor VII (human) + coagulation factor IX (human) + coagulation factor X (human) + protein C (human) + protein S (human)) - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Antibodies for Undisclosed Indication - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
antihemophilic factor (recombinant), single chain - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
C1 esterase inhibitor (human) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CSL-112 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CSL-311 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CSL-312 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CSL-324 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CSL-346 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CSL-626 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CSL-640 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CSL-650 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CSL-689 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CSL-777 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
factor XIII (human) - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
fibrinogen (human) - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
haptoglobin + hemopexin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
immune globulin (human) - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Monoclonal Antibodies for Undisclosed Indication - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
PODCRC-OHS - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Recombinant Protein for Bleeding and Clotting Disorders - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Recombinant Protein for Hemophilia - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CSL Ltd - Pipeline Analysis 50
CSL Ltd - Pipeline Products by Target 50
CSL Ltd - Pipeline Products by Route of Administration 52
CSL Ltd - Pipeline Products by Molecule Type 53
CSL Ltd - Pipeline Products by Mechanism of Action 54
CSL Ltd - Dormant Projects 56
CSL Ltd - Company Statement 57
CSL Ltd - Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

CSL Ltd, Key Facts 6
CSL Ltd - Pipeline by Indication, 2016 8
CSL Ltd - Pipeline by Stage of Development, 2016 10
CSL Ltd - Monotherapy Products in Pipeline, 2016 11
CSL Ltd - Combination Treatment Modalities in Pipeline, 2016 12
CSL Ltd - Partnered Products in Pipeline, 2016 13
CSL Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14
CSL Ltd - Out-Licensed Products in Pipeline, 2016 15
CSL Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
CSL Ltd - Pre-Registration, 2016 17
CSL Ltd - Phase III, 2016 18
CSL Ltd - Phase II, 2016 19
CSL Ltd - Phase I, 2016 20
CSL Ltd - Preclinical, 2016 21
CSL Ltd - Discovery, 2016 22
CSL Ltd - Pipeline by Target, 2016 51
CSL Ltd - Pipeline by Route of Administration, 2016 52
CSL Ltd - Pipeline by Molecule Type, 2016 53
CSL Ltd - Pipeline Products by Mechanism of Action, 2016 55
CSL Ltd - Dormant Developmental Projects,2016 56
CSL Ltd, Other Locations 58
CSL Ltd, Subsidiaries 59